Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Background. Long-lasting dyshormonal breast diseases in women represent a risk factor for breast cancer, especially in patients with atypia. Clinical manifestations of fibrocystic breast disease (FBD) and mastopathy, including high-intensity pain cause psychoemotional discomfort and reduce the quality of life of women. The search for effective management strategies for mastopathy with an antiproliferative effect is highly relevant.Aim. To assess clinical and radiological efficacy of a new conservative treatment for FBD, “Evening primrose oil” administered orally for 6 months in women with symptomatic FBD.Materials and methods. This randomized, blind, placebo-controlled trial included 144 patients with clinical FBD manifestations (pain and tension in the breast). Patients were randomly assigned to one of the two treatment groups. Women in group I received “Evening primrose oil”, whereas women in group II received placebo (ascorbic acid) for 6 months. We measured the dynamics of radiological findings (at mammography and ultrasound examination) in the breast before and after treatment, as well as pain intensity using the visual-analog scale.Results. Patients in group I with all types of FBD (diffuse mastopathy, nodular, and mixed forms) demonstrated positive dynamics and BI-RADS category downgrading within 6 months. In the placebo group, the examination after 6 months demonstrated no significant changes in the breast and no BI-RADS category downgrading among women with diffuse mastopathy. Some patients with nodular and mixed FBD receiving placebo had negative dynamics after 6 months (as demonstrated by mammography and ultrasound examination; BI-RADS category upgraded from II to III, p<0.01). Patients receiving “Evening primrose oil” also showed positive dynamics in their clinical manifestations, including decreased breast pain (from 7.8 to 1.8 on the visual analog scale). By contrast, patients receiving placebo had no changes in their breast pain intensity after 6 months (from 7.3 to 7.1 on the visual analog scale), which resulted in poorer psychoemotional state in 55.6 % of women.Conclusion. Our new treatment strategy for FBD patients with clinical and radiological manifestations in the breast demonstrated high efficiency and can be implemented into routine clinical practice.
Background. Long-lasting dyshormonal breast diseases in women represent a risk factor for breast cancer, especially in patients with atypia. Clinical manifestations of fibrocystic breast disease (FBD) and mastopathy, including high-intensity pain cause psychoemotional discomfort and reduce the quality of life of women. The search for effective management strategies for mastopathy with an antiproliferative effect is highly relevant.Aim. To assess clinical and radiological efficacy of a new conservative treatment for FBD, “Evening primrose oil” administered orally for 6 months in women with symptomatic FBD.Materials and methods. This randomized, blind, placebo-controlled trial included 144 patients with clinical FBD manifestations (pain and tension in the breast). Patients were randomly assigned to one of the two treatment groups. Women in group I received “Evening primrose oil”, whereas women in group II received placebo (ascorbic acid) for 6 months. We measured the dynamics of radiological findings (at mammography and ultrasound examination) in the breast before and after treatment, as well as pain intensity using the visual-analog scale.Results. Patients in group I with all types of FBD (diffuse mastopathy, nodular, and mixed forms) demonstrated positive dynamics and BI-RADS category downgrading within 6 months. In the placebo group, the examination after 6 months demonstrated no significant changes in the breast and no BI-RADS category downgrading among women with diffuse mastopathy. Some patients with nodular and mixed FBD receiving placebo had negative dynamics after 6 months (as demonstrated by mammography and ultrasound examination; BI-RADS category upgraded from II to III, p<0.01). Patients receiving “Evening primrose oil” also showed positive dynamics in their clinical manifestations, including decreased breast pain (from 7.8 to 1.8 on the visual analog scale). By contrast, patients receiving placebo had no changes in their breast pain intensity after 6 months (from 7.3 to 7.1 on the visual analog scale), which resulted in poorer psychoemotional state in 55.6 % of women.Conclusion. Our new treatment strategy for FBD patients with clinical and radiological manifestations in the breast demonstrated high efficiency and can be implemented into routine clinical practice.
Introduction. The issues of dispensary check-ups for women with benign breast diseases (BBD) still remain an urgent challenge. What stands out are delayed visits to the doctor, irregular examinations and failure to follow prescribed therapy. Women’s health schools equipped with state-of-the -art information and communication technologies contribute to improving motivation for regular check-ups, timely examinations and adherence to treatment.Aim. To study the impact of training on adherence to regular visits, examination and treatment provided to a dispensary group of women with BBD at the Prevention School.Materials and methods. A total of 486 women with BBD who attended the Women’s Health Prevention School were observed. A professional medical advice included a gynaecological screening and consultation with an oncologist, breast ultrasound imaging for women of all age groups and mammography for women aged 40 years and older; once diffuse benign changes to breast tissues were detected, the women were prescribed Mastodynon (Bionorica SE) for 3 months.Results. After training, the rates of visits to a doctor increased from 69.3% to 94.2%, the examination rates increased from 66.8% to 88.6%, adherence to regular therapy increased from 43.6% to 82.9%. 82.9% of women reported health improvements after therapy with the herbal medicine, 7.6% – absence of changes, 4.3% – deterioration in the condition, of which 2.6% – menstrual disorders, 5.2% women discontinued therapy (due to poor tolerance – 3.6%, skin reactions – 1.0%, family reasons – 0.6%).Conclusion. Raising women’s awareness about breast cancer and a set of measures increase the early detection of breast diseases and women’s cancer alertness.
Aim to compare the results of vacuum aspiration biopsy (VAB) and sectoral resection in the treatment of benign breast tumors. Material and methods.During the study we compared the results of treatment in two groups of patients. The main group included 50 patients (mean age 54.830.934 years) who underwent VAB, the control group comprised 55 patients (mean age 55.7041.998 years) who underwent sectoral resection. Before the surgery, a tumor biopsy was performed with the following cytological and histological examination. The diagnosis of fibroadenoma was predominant. After the operation, a histological analysis of the received preparations was done. We assessed the immediate postoperative results, such as: blood loss, operation time, intensity of pain syndrome, bed-day number, quality of life after the operation. Results.The duration of surgery was significantly lower in patients with VAB than in patients with sectoral resection (p=0.000). The blood loss after surgery did not differ significantly (p=0.921) and did not exceed 10 ml in both groups. The groups under study were comparable according to the results of the histological examination (Student's t-test was 0.501, p=0.651). In each group, the pain syndrome was assessed in the postoperative period according to a 10-point pain scale after 3 hours, 8 hours, 24 hours, 3 days, 5 days and 10 days after surgical intervention. In the VAB group, the scores were significantly lower, p=0.000. The average number of bed-days in patients of the control group was 10.322.814, in the main group 1 day, the difference was statistically significant (p=0.000). The frequency of possible complications (hematoma, seroma, infection, deformity of the mammary gland, residual masses after removal) was significantly lower (p=0.013) in patients of the main group. When assessing the life quality of patients after surgery with the MOS SF-36 questionnaire, we found that the indicators were significantly higher in patients of the VAB group (Psychological Health Scale p=0.008, Social Functioning Scale p=0.003, Physical Condition Scale p=0.041).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.